Adagene Inc.
ADAG
$2.45
-$0.04-1.61%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
1/23/2026
-
TipRanks Financial Blog
1/23/2026
-
The Fly
1/23/2026
-
GuruFocus
1/23/2026
-
Globe Newswire
1/16/2026
-
MarketBeat
1/4/2026
-
MarketBeat
12/28/2025
-
MarketBeat
12/18/2025
-
MarketBeat
12/17/2025
-
Nasdaq News: Stocks
12/17/2025
-
Zacks Investment Research
12/16/2025
-
GuruFocus
12/16/2025
-
Seeking Alpha - Healthcare
12/16/2025
-
The Fly
12/16/2025
-
GuruFocus
12/16/2025
-
Globe Newswire
12/10/2025
-
MarketBeat
11/24/2025
-
GuruFocus
11/24/2025
-
The Fly
11/24/2025
-
The Fly
11/16/2025
-
MarketBeat
11/16/2025
-
MarketBeat
11/15/2025
-
Ticker Report
11/15/2025
-
Ticker Report
11/14/2025
-
The Fly
11/13/2025
-
GuruFocus
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, August 12, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Mar 23 and 27 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
86 512 8777 3632
Address
Building C14
4th Floor - No. 218, Xinghu Street
Suzhou Industrial Park Suzhou, 215123
4th Floor - No. 218, Xinghu Street
Suzhou Industrial Park Suzhou, 215123
Country
Year Founded
Business Description
Sector
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead...
more